An­timi­cro­bial re­sis­tance: FDA dis­cuss­es re­im­burse­ment re­forms

Re­im­burse­ment re­forms for an­timi­cro­bial treat­ments could in­clude “a mix of mile­stone pay­ments and sub­scrip­tion fees for de­vel­op­ers of FDA-ap­proved prod­ucts with high eco­nom­ic and clin­i­cal val­ue, tar­get­ed at mul­ti-drug re­sis­tant or­gan­isms and linked to proven clin­i­cal out­comes,” FDA Com­mis­sion­er Scott Got­tlieb said in a speech at Pew Char­i­ta­ble Trusts on Fri­day.

He al­so of­fered the idea of us­ing a “sub­scrip­tion-based mod­el” that could see hos­pi­tals pay­ing a flat rate for ac­cess to a cer­tain num­ber of dos­es of a new an­timi­cro­bial.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA